Skip to content

Myopia Control Efficacy of Second-generation DIMS Spectacle Lenses on Fast Progressing Myopes - Auxiliary Group

Myopia Control Efficacy of Second-generation DIMS Spectacle Lenses on Fast Progressing Myopes - Auxiliary Group

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05888805
Enrollment
59
Registered
2023-06-05
Start date
2023-07-29
Completion date
2028-12-31
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myopia

Keywords

Myopia, Defocus

Brief summary

The purpose of this study is to examine the efficacy and performance of the Defocus Incorporated Multiple Segments (DIMS) and a variant of DIMS (D2) spectacle lenses on controlling myopia progression in fast progressing myopic children.

Detailed description

DIMS spectacle lens is a multifocal spectacle lens that produces myopic defocus images and corrects distance refractive errors at the same time. Participants will be prescribed a pair of DIMS spectacle lenses. Their cycloplegic refraction and axial length will be monitored every 6 months over the first 2 years. They will then be prescribed with a pair of D2 spectacle lens for an additional 2 years. D2 is the variant of Defocus Incorporated Spectacle lenses. It is a multifocal spectacle lens that produces myopic defocus images and corrects distance refractive errors at the same time.

Interventions

OTHERDIMS spectacle lens

DIMS spectacle lens is a multifocal spectacle lens that corrects the distance refraction and provides myopic defocus simultaneously.

Sponsors

The Hong Kong Polytechnic University
Lead SponsorOTHER
HOYA Lens Thailand LTD.
CollaboratorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Participants will be prescribed with a pair of DIMS spectacle lenses for 24 months. They will then be prescribed with a pair of D2 spectacle lenses for an additional 24 months.

Eligibility

Sex/Gender
ALL
Age
4 Years to 12 Years
Healthy volunteers
Yes

Inclusion criteria

* SER: -1.00D or below * Documented history of fast progressing myopia, either in SER or AL * SER progression: 0.50D/year or more * AL elongation: 0.27mm/year or more * Best-corrected monocular visual acuity (VA) in both eyes: 0.00 logMAR (equivalent) or better * Acceptance of random group allocation and the masked study design * Anisometropia of 1.50 D or less * Astigmatism of 2.00 D or less

Exclusion criteria

* Strabismus and binocular vision abnormalities * Ocular and systemic abnormalities * Prior experience of myopia control

Design outcomes

Primary

MeasureTime frameDescription
Cycloplegic refraction change in spherical equivalent refraction (SER)Baseline, every 6 months for 4 yearsCycloplegic SER (in diopter) will be measured using an open field autorefractor. Change in SER with cycloplegia from the baseline every 6 months over the 4-year study will be measured

Secondary

MeasureTime frameDescription
Axial length changeBaseline, every 6 months for 4 yearsAxial length (mm) will be measured after cycloplegia using a non-contact optical biometer. Change in axial length from the baseline every 6 months over the 4-year study will be measured

Countries

Hong Kong

Contacts

PRINCIPAL_INVESTIGATORDennis Yan Yin Tse, PhD

School of Optometry, The Hong Kong Polytechnic University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026